Karl D. Lewis, MD, on Selecting Patients for Treatment With Cemiplimab-rwlc

Posted: Monday, October 14, 2019

For which patients with cutaneous squamous cell carcinoma would you consider treatment with an anti–PD-1 antibody such as cemiplimab-rwlc?